The New York Times substantially revised a story about Medvi, a vibe-coded telehealth startup, after the original article omitted information about the company’s business practices. The paper said the piece should have included that information.
Medvi, an AI-powered GLP-1 drug marketer, responds after allegations about fake clients and fake doctors. Its response raises more questions amid intense scrutiny and an FDA warning.
The New York Times offers a glowing portrait of Medvi, a two-person private company reporting $401 million in 2025 revenue from 250,000 customers and no investors. The portrait is described as viral and highly questionable, while other outlets examine Medvi’s FDA warning letter and affiliate ads.
Apr 2026 · Telehealth and Telecare AwareNews article
Techdirt examines The New York Times’ profile of Medvi, an AI-built GLP-1 telehealth marketer, and the criticism that followed. The piece frames the coverage as a case of the Times being misled and treating the company as a sign of AI’s future.
